GLP-1 and Nicotine Addiction: Can Semaglutide Help You Quit?

Medically Reviewed by Dr. Kenneth Spielvogel, MD, Senior Medical Officer at Carrara Treatment

Can GLP-1 receptor agonists like semaglutide help you quit smoking? While traditionally prescribed for type 2 diabetes and weight management, emerging clinical research reveals that GLP-1 medications target the brain’s mesolimbic reward system to suppress nicotine cravings. Furthermore, by regulating metabolic rate and satiety, these medications address the single greatest barrier to smoking cessation: post-quit weight gain.

Key Takeaways

• Dual-Action Therapy: GLP-1 receptor agonists uniquely target both the neurological pathways driving nicotine cravings and the metabolic changes that cause weight gain after quitting.
• Dampened Cravings: Recent 2026 clinical data demonstrates that semaglutide significantly reduces daily cigarette consumption and subjective cravings by modulating dopamine release in the brain’s reward centers.
• Preventing Post-Quit Weight Gain: While the average person gains 8 to 11 pounds in the first year after quitting smoking, clinical trials show that GLP-1 users maintain or lose weight during cessation.
• The Dopamine Shield: By stabilizing dopamine transmission, GLP-1 receptor agonists blunt the anticipatory pleasure associated with smoking cues, making cigarettes less appealing.
• The Carrara Protocol: At Carrara, we integrate these cutting-edge medical insights into our comprehensive Stage 2 (Metabolic Repair) program, combining clinical stabilization with intensive somatic and behavioral therapies.

The Double-Edged Sword of Smoking Cessation

Quitting smoking is one of the most significant actions an individual can take to improve their health, yet long-term abstinence remains notoriously difficult to achieve. While nicotine withdrawal triggers intense physical and psychological cravings, many smokers face a secondary, highly formidable barrier: post-cessation weight gain [1].

Nicotine is a powerful metabolic stimulant and appetite suppressant. It affects body weight through several distinct physiological mechanisms:
– Metabolic Elevation: Nicotine temporarily increases resting metabolic rate by approximately 6% within twenty minutes of smoking, translating to an extra 140 to 200 kilocalories burned daily [1].
– Appetite Suppression: Nicotine binds to nicotinic acetylcholine receptors in the hypothalamus, activating pro-opiomelanocortin (POMC) neurons to signal satiety and reduce food intake [1].
– Behavioral Substitution: Smoking often serves as a physical, oral alternative to eating, helping individuals manage stress without consuming calories.

When a person quits smoking, these metabolic and behavioral supports are abruptly removed. The metabolic rate drops back to baseline, appetite surges, and the individual often substitutes food for cigarettes to satisfy the brain’s demand for oral stimulation and dopamine.

As a result, a meta-analysis reveals that individuals gain an average of 8 to 11 pounds (4 to 5 kilograms) within the first year of quitting smoking, with the majority of this gain occurring in the first three months [1]. For many, the psychological distress of rapid weight gain, combined with persistent nicotine cravings, leads directly to relapse [1].

The Dual Mechanism of GLP-1 Receptor Agonists

Traditional smoking cessation aids, such as nicotine replacement therapy (NRT), varenicline, and bupropion, can help manage withdrawal symptoms and temporarily delay weight gain [1]. However, their long-term efficacy is limited, and they do not prevent post-cessation weight gain once the treatment ends [1].

Glucagon-like peptide-1 (GLP-1) receptor agonists represent a paradigm shift in addiction medicine. Because GLP-1 receptors are expressed in both the metabolic centers of the hypothalamus and the reward pathways of the midbrain, these medications offer a unique, dual-action therapeutic profile [1].

                    ┌─────────────────────────┐
                    │  GLP-1 Receptor Agonist │
                    └────────────┬────────────┘
                                 │
         ┌───────────────────────┴───────────────────────┐
         ▼                                               ▼
┌──────────────────────────────┐               ┌──────────────────────────────┐
│  Hypothalamic Satiety Nodes  │               │  Mesolimbic Reward Circuit   │
├──────────────────────────────┤               ├──────────────────────────────┤
│ - Delays Gastric Emptying    │               │ - Blunts Dopamine Spikes     │
│ - Stimulates POMC Neurons    │               │ - Reduces Cue Reactivity     │
│ - Prevents Post-Quit Weight  │               │ - Dampens Nicotine Craving   │
└──────────────────────────────┘               └──────────────────────────────┘

By simultaneously targeting these two distinct systems, GLP-1 receptor agonists address the physical addiction to nicotine while insulating the patient from the metabolic consequences of quitting.

What the 2024-2026 Research Shows

A surge of clinical and epidemiological studies published between 2024 and 2026 has provided robust evidence supporting the use of GLP-1 receptor agonists for nicotine cessation.

1. The Hendershot Semaglutide RCT (JAMA Network Open, May 2026)

In a landmark randomized clinical trial published in JAMA Network Open, a collaborative team of researchers from the University of Southern California and the University of North Carolina evaluated the effects of once-weekly semaglutide (titrated to 0.5 mg/week) versus placebo in adults with daily cigarette use [2] [3].

The trial revealed that semaglutide users demonstrated:
– A significant increase in “smoking resistance,” measured by the ability to delay smoking when presented with active cigarette cues in a laboratory setting [2].
– A marked reduction in daily cigarette consumption and subjective craving scores throughout the eight-week treatment period [2].
– Complete mitigation of post-cessation weight gain, with semaglutide users maintaining or losing weight, while the placebo group experienced significant weight gain [2].

This study represents the first dedicated randomized clinical trial confirming that semaglutide is highly effective at reducing nicotine cravings and smoking behaviors in daily smokers.

2. The Riyadh Hospital Registry Study (BMC Public Health, February 2026)

A massive real-world study published in BMC Public Health analyzed electronic medical records from 13,232 patients across seven major hospitals [4]. In the second phase of the study, researchers surveyed a cohort of patients who had been using GLP-1 medications (primarily semaglutide) for at least three months [4].

The findings were striking:
– Among active smokers who initiated GLP-1 therapy, 17.4% became complete ex-smokers within the treatment period [4].
– An additional 24.4% of participants reported a significant reduction in nicotine cravings and daily tobacco use [4].
– Semaglutide was the most frequently prescribed agent, demonstrating the strongest real-world correlation with spontaneous smoking cessation [4].

3. The Xavier Meta-Analysis (American Psychiatric Association, May 2025)

Presented at the American Psychiatric Association’s Annual Meeting, a systematic review and meta-analysis led by Dr. Debora Xavier, MD, evaluated data from randomized controlled trials representing 410 patients undergoing smoking cessation [5].

The meta-analysis concluded that GLP-1 receptor agonists significantly reduced post-cessation weight gain [5]. While control groups gained weight, GLP-1 users experienced a net weight loss during the quit attempt [5]. Dr. Xavier noted:

“GLP-1 receptor agonists may offer a promising path to help smokers quit by addressing one of their biggest concerns: weight gain. Their neuromodulation effects can potentially reduce the rewarding effects of both nicotine and food.” [5]

Neurobiological Insights: How GLP-1 Blunts Nicotine Reward

At the neurochemical level, the rewarding effects of nicotine are mediated by the mesolimbic dopamine pathway, which projects from the ventral tegmental area (VTA) to the nucleus accumbens (NAc) [6]. When nicotine is inhaled, it binds to nicotinic receptors in the VTA, triggering a rapid release of dopamine in the NAc that reinforces the smoking behavior [6].

GLP-1 receptors are highly expressed on the dopamine-producing neurons of the VTA and the receiving neurons of the NAc [6]. When a GLP-1 receptor agonist binds to these central receptors, it initiates several neurobiological changes:
– Dampening Phasic Dopamine: It reduces the sudden, sharp spikes in dopamine that occur when a smoker encounters a cue (such as the smell of smoke or the sight of a lighter) [6].
– Attenuating Nicotine-Induced Locomotion: Preclinical models show that GLP-1 receptor activation prevents the physical, hyperactive response to nicotine administration [6].
– Enhancing Excitatory Drive in Avoidance Pathways: GLP-1 signaling activates projections from the nucleus of the solitary tract (NTS) to the medial habenula, a pathway known to promote avoidance behaviors and suppress drug reward [6].

By stabilizing this neural circuitry, GLP-1 medications act as a “dopamine shield,” ensuring that smoking a cigarette no longer delivers the expected surge of pleasure, while simultaneously quelling the physical drive to smoke. This same mechanism has shown promise for alcohol cravings and opioid dependence.

Comparing Nicotine Cessation Therapies

To understand where GLP-1 receptor agonists fit into the clinical landscape, it is helpful to compare them to traditional smoking cessation methods:

Therapeutic Class	Mechanism of Action	Impact on Cravings	Impact on Post-Quit Weight Gain	Common Side Effects
Nicotine Replacement (NRT)	Delivers low-dose nicotine to prevent acute withdrawal.	Moderate	Delays weight gain temporarily; does not prevent it [1].	Local irritation, sleep disturbances.
Varenicline (Chantix)	Partial nicotinic receptor agonist; blocks nicotine binding.	High	Delays weight gain temporarily; does not prevent it [1].	Nausea, vivid dreams, mood changes.
Bupropion (Wellbutrin)	Norepinephrine-dopamine reuptake inhibitor.	Moderate	Delays weight gain temporarily; does not prevent it [1].	Insomnia, dry mouth, agitation.
GLP-1 Agonists (e.g., Semaglutide)	Modulates mesolimbic dopamine and hypothalamic satiety [1].	High [2] [4].	Actively prevents weight gain; promotes weight loss [2] [5].	Mild nausea, transient gastrointestinal upset.

The Carrara Approach: Comprehensive Recovery and Metabolic Repair

At Carrara Treatment, we recognize that nicotine dependence is a complex, deeply ingrained behavioral and physiological pattern. While GLP-1 receptor agonists represent a revolutionary medical tool to manage cravings and protect metabolic health, they are most effective when integrated into a structured, multidisciplinary program.

Within our Stage 2: Metabolic Repair (Weeks 2–12) protocol, we utilize these advanced medications (strictly off-label under close medical supervision) as a stabilizing foundation. By quieting the physical distress of nicotine withdrawal and preventing the anxiety associated with weight gain, we create a safe, stable window for our clients to engage in deep psychological and physical healing.

Our integrated protocol includes:
– Somatic Experiencing: Addressing the underlying nervous system dysregulation and stress patterns that originally drove the need to smoke.
– Targeted Nutraceuticals: Utilizing specific amino acids, such as N-acetylcysteine (NAC) and L-Theanine, to support natural neurotransmitter synthesis and accelerate the repair of the blood-brain barrier.
– Personalized Fitness and Nutrition: Designing gourmet, nutrient-dense meal plans and low-impact exercise regimens to naturally boost metabolic rate and support cardiovascular restoration.

By combining cutting-edge pharmacotherapy with premium, compassionate care, we empower our clients to break free from nicotine dependence without sacrificing their physical or emotional well-being.

“At Carrara, we believe GLP-1 medications may represent one of the most important breakthroughs in addiction medicine in decades, not simply because they can reduce appetite, but because many patients report a meaningful reduction in cravings, compulsive reward-seeking, and the constant ‘mental noise’ surrounding alcohol, food, and other substances. We are seeing emerging evidence, supported by growing clinical experience, that these medications may help regulate the same reward and dopamine pathways that drive addictive behavior.”

“That said, we do not view GLP-1s as a standalone cure. At Carrara, they are integrated into a broader recovery and resilience model that includes exercise, metabolic optimization, behavioral treatment, nutrition, sleep, nervous system regulation, and long-term rebuilding of both physical and mental health.”

— Dr. Kenneth Spielvogel, MD, Senior Medical Officer, Carrara Treatment

Begin Your Healing at Our Luxury Malibu Estates

If you are ready to overcome nicotine dependence in a highly supportive, clinically sophisticated environment, Carrara Treatment is here to help you take the first step.

Our ultra-private, luxury estates in Malibu offer a sanctuary for complete physical and mental restoration. With 24/7 medical supervision, gourmet dining, and a dedicated team of elite clinicians, we provide the ultimate foundation for lasting wellness.

Contact our admissions team today for a confidential consultation at (888) 383-5207.

Frequently Asked Questions

Can semaglutide help me quit smoking or vaping?

Yes, a landmark May 2026 randomized controlled trial published in JAMA Network Open demonstrated that daily smokers taking semaglutide had a significantly higher rate of smoking resistance and reduced nicotine cravings compared to placebo. GLP-1 medications stabilize the same dopamine reward pathways hijacked by nicotine.

Do GLP-1 medications prevent weight gain after quitting smoking?

One of the greatest barriers to quitting smoking is the fear of post-cessation weight gain. Traditional cessation aids do not address this, but GLP-1 receptor agonists actively regulate metabolic satiety and prevent weight gain, making them a unique and highly attractive dual-benefit option for individuals looking to quit smoking.

How does Carrara integrate nicotine cessation into addiction treatment?

At Carrara, we recognize that nicotine use often co-occurs with other substance use disorders. We provide a highly supportive environment where clients can address all dependencies simultaneously. We combine medically supervised GLP-1 therapy with customized fitness, nutrition, and somatic trauma healing to rebuild overall physical and neurological resilience.

References

[1] Ahmed GU, Zehra E, Rasheed S, et al. GLP-1 receptor agonists for smoking cessation: a narrative review of weight management potential. Annals of Medicine and Surgery. 2026;88(3):2373-2382. doi:10.1097/MS9.0000000000004725.

[2] Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial. JAMA Network Open. 2026;9(5):e2614898. doi:10.1001/jamanetworkopen.2026.14898.

[3] Hendershot CS. Therapeutic potential of GLP-1 receptor agonists for smoking cessation. Biological Psychiatry. 2026;99(8):e1185. doi:10.1016/j.biopsych.2026.01.185.

[4] Alsaleh NA, Alsharif AA, Joharji H, et al. The use of GLP-1 receptor agonists and subsequent risk of nicotine-related events: a cross-sectional study. BMC Public Health. 2026;26:915. doi:10.1186/s12889-026-26474-6.

[5] Xavier D. New Research: GLP-1 Receptor Agonists May Support Nicotine Cessation. American Psychiatric Association Annual Meeting Press Release. May 17, 2025. Available at: https://www.psychiatry.org/news-room/news-releases/new-research-glp-1-agonists-and-nicotine-cessation.

[6] Völker KM, Prechtl BLH, Bormann NL, Choi DS. The potential role of GLP-1 receptor agonists in substance use disorders – a systematic review. Frontiers in Pharmacology. 2026;16:1702448. doi:10.3389/fphar.2025.1702448.